Stocks Crossing 50-Day SMA 04/01: (BBRY) (ALXN) (SODA) Above; (CSCO) (ZNGA) (BCRX) Below
- Top 10 News for 8/25 - 8/29: S&P 500's New Record; U.S. Q2 GDP Outpaces Views; Major Mergers Aplenty
- AIG's (AIG) Peter Hancock Assumes CEO Role; Benmosche Becomes Advisor
- Pressure on U.S. to Update Terror Alert System After U.K. Raises Terror Threat Level
- FTC Requests Additional Info from Reynolds American (RAI), Lorillard (LO) on Pending Deal
Crossing and above:
- BlackBerry (Nasdaq: BBRY) - up 4.6 percent. Shares popping up higher amid some positive analyst commentary Monday. With AT&T (NYSEL T) and Verizon Wireless (NYSE: VZ) starting sales of the Z10 handset in the U.S., many are scrambling to get a good read of what implications might be on margins and overall growth several quarters from now. For more on analyst comments, click here.
- Alexion Pharma (Nasdaq: ALXN) - up 3.7 percent. Alexion bouncing back after receiving a cGMP warning letter from the FDA last week.
- SodaStream International Ltd. (Nasdaq: SODA) - up 3.1 percent. SodaStream popping back over the $50 level with volume. A finish higher today would put SodaStream ending better seven of the last eight sessions.
- Zynga, Inc. (Nasdaq: ZNGA) - down 6.0 percent. Moving lower amid reports that Facebook (Nasdaq: FB) might debut its own, dedicated Home screen for Google's (Nasdaq: GOOG) Android mobile OS on Thursday. The move would put further separation between the two companies as Facebook appears to shift focus away from games.
- Cisco Systems, Inc. (Nasdaq: CSCO) - down 0.3 percent. Overall pressure in the tech segment is offsetting a 20 percent-plus dividend raise announced last week. For more color, click here.
- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) - up 16.8 percent. Reported receiving a preliminary comment letter from the U.S. Food & Drug Administration (FDA) that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of intravenous (i.v.) peramivir. The letter was sent in response to questions BioCryst submitted to the FDA in advance of an upcoming Type C regulatory meeting regarding i.v. peramivir.
You May Also Be Interested In
- UPDATE: Instagram (FB) Down for Some Users
- United Therapeutics (UTHR) Gains After Judge Rules Remodulin Patents are Not Invalid
- UPDATE: Criteo (CRTO) Sees Sharp Move Lower; Talks with Publicis 'Unfounded' - Reuters